Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Biomedicines Année : 2023

Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?

Résumé

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) is involved in numerous physiological functions and plays a key role in pain modulation including neuropathic pain. Diabetic neuropathy is a common complication of diabetes mellitus often accompanied by chronic neuropathic pain. Animal models of diabetes offer relevant tools for studying the pathophysiological mechanisms and pharmacological sensitivity of diabetic neuropathic pain and for identifying new therapeutic targets. In this review, we report data from preclinical work published over the last 15 years on the analgesic activity of drugs acting on the serotonergic system, such as serotonin and noradrenaline reuptake inhibitor (SNRI) antidepressants, and on the involvement of certain serotonin receptors-in particular 5-HT1A, 5-HT2A/2c and 5-HT6 receptors-in rodent models of painful diabetic neuropathy.
Fichier principal
Vignette du fichier
Mokhtar et al., 2023 Biomedicines.pdf (515.51 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

hal-04323925 , version 1 (06-12-2023)

Identifiants

Citer

Nazarine Mokhtar, Stephane Doly, Christine Courteix. Diabetic Neuropathic Pain and Serotonin: What Is New in the Last 15 Years?. Biomedicines, 2023, Pathological Mechanisms in Diabetes 2.0, 11 (7), pp.1924. ⟨10.3390/biomedicines11071924⟩. ⟨hal-04323925⟩
17 Consultations
25 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More